[1] Mathew, S., Kuttan, G. Immunomodulatory and antitumour activities of Tinospora cordifolia. Fitoterapia 70 (1999) 35 - 43.
[2] Bishayi, B., Roychowdhury, S., Ghosh, S. and Sengupta, M. Hepatoprotective and immunomodulatory properties of Tinospora Cordifolia in CCl4 intoxicated mature albino rats. The Journal of Toxicological Sciences, Vol.27, No.3, 139-146, 2002.
[3] Manjrekar, P. N., Jolly, C. I., Narayanan, S. Comparative studies of the immunomodulatory activity of Tinospora cordifolia and Tinospora sinensis. Fitoterapia 71 (2000) 254 - 257.
[4] Kapil, A., Sharma, S. Immunopotentiating compounds from Tinospora cordifolia. Journal of Ethnopharmacology 58 (1997) 89 - 95.
[5] Jagetia, G. C., Rao, S. K. Evaluation of the Antineoplastic Activity of Guduchi (Tinospora cordifolia) in Ehrlich Ascites Carcinoma Bearing Mice. Biol. Pharm. Bull. 29(3) 460—466 (2006).
[6] Goel, H. C. et al. Radioprotective Potential of an Herbal Extract of Tinospora cordifolia. J. Radiat. Res., 45, 57–64 (2004).
[7] Babu, R. et al. A randomized, double-blind, placebo-controlled, proof of concept study to assess the safety and efficacy of Carica papaya and Tinospora cordifolia leaf extract (Thrombobliss) in subjects undergoing chemotherapy treatment and subjects with systemic microbial infection and subsequent reduction in platelet count. International Journal of Clinical Trials 2017 Aug;4(3):116-121.
[8] Aher, V. D., Wahi, A. Pharmacological study of Tinospora Cordifolia as an Immunomodulator. International Journal of Current Pharmaceutical Research ISSN- 0975-1491, Vol 2, Issue 4, 2010.
[9] Desai, V. R., Kamat, J. P., Sainis, K. B. An immunomodulator from Tinospora cordifolia with antioxidant activity in cell-free systems. Proc. Indian Acad. Sci. (Chem. Sci.), Vol. 114, No. 6, December 2002, pp 713–719.
[10] Abood, W. N., Fahmi, I., Abdulla, M. A. and Ismail, S. Immunomodulatory effect of an isolated fraction from Tinospora crispa on intracellular expression of INF-γ, IL-6 and IL-8. BMC Complementary and Alternative Medicine 2014, 14:205.
[11] Ranjith, M. S. et al. Enhanced Phagocytosis and Antibody Production by Tinospora cordifolia - A new dimension in Immunomodulation. African Journal of Biotechnology, ISSN 1684–5315, Vol. 7 (2), pp. 081-085, 18 January, 2008.
[12] Bairy, K. L., Rao Y., and Kumar, K. B. Efficacy of Tinospora cordifolia on Learning and Memory in Healthy Volunteers: A Double-Blind, Randomized, Placebo Controlled Study. Iranian Journal Of Pharmacology & Therapeutics, Razi Institute for Drug Research (RIDR) 3:57-60, 2004.
[13] Sannegowda, K. M., Venkatesha, S. H., and Moudgil, K. D. Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage. International Journal of Immunopathology and Pharmacology 2015, Vol. 28(4) 521–531.
[14] Rajalakshmi, M., Eliza, J., Priya, C. E., A, N., and Daisy, P. Anti-diabetic properties of Tinospora cordifolia stem extracts on streptozotocin- induced diabetic rats. African Journal of Pharmacy and Pharmacology Vol. 3(5). pp. 171-180, May, 2009.
[15] Ahmad, W., Jantan, I., Kumolosasi, E., Bukhari, S. N. A., Immunostimulatory effects of the standardized extract of Tinospora crispa on innate immune responses in Wistar Kyoto rats. Drug Design, Development and Therapy, Dovepress, 10 June 2015.
[16] Singh, S. S., Pandey, S. C., Srivastava, S., Gupta, V. S., Patro, B., Ghosh, A. C. Chemistry and medicinal properties of tinospora cordifolia (guduchi). Indian Journal of Pharmacology 2003; 35: 83-91.
[17] Aiyer KN, Kolammal M, editors. Pharmacognosy of Ayurvedic Drugs, Series 1. 1st ed. Trivendram: The Central Research Institute; 1963.
[18] Raghunathan K, Mittra R, editors. Pharmacognosy of Indigenous Drugs. New Delhi: Central Council for Research In Ayurveda & Siddha; 1982.
[19] Nadkarni KM, Nadkarni AK, editors. Indian Materia Medica, Vol 1. 3rd ed. Mumbai: M/S Popular Prakasan Pvt. Ltd; 1976.
[20] Kirtikar KR, Basu BD, editors. Indian Medicinal Plants, Vol 1. 2nd ed. New Connaught Place, Dehra Dun: M/S Bishen Singh, Mahendra Pal Singh; 1975.
[21] Zhao TF, Wang X, Rimando AM, Che C. Folkloric medicinal plants: Tinospora sagittata var. cravaniana and Mahonia bealei. Planta Med 1991;57:505.
[22] Ikram M, Khattak SG, Gilani SN. Antipyretic studies on some indigenous Pakistani medicinal plants: II. J Ethnopharmacol 1987;19:185-92.
[23] Nayampalli SS, Desai NK, Ainapure SS. Anti-allergic properties of Tinospora cardifolia in animal models. Indian J Pharm 1986;18:250-2.
[24] Rai M, Gupta SS. The deposition of the secondary salts over the five pellets in rats was inhibited by the aqueous extract of T. cordifolia. J Res Ind Med 1966;10:113-6.
[25] Pendse VK, Dadhich AP, Mathur PN, Bal MS, Madam BR. Anti-inflammatory, immunosuppressive and some related pharmacological actions of the water extract of Neem Giloe (Tinospora cordifolia)-A preliminary report. Indian J Pharm 1977;9:221-4.
[26] Asthana JG, Jain S, Mishra A, Vijaykanth MS. Evaluation of antileprotic herbal drug combinations and their combination with Dapsone. Indian Drugs 2001;38:82-6.
[27] Anonymous. Wealth of India: Raw materials, Vol X. New Delhi: CSIR; 1976.
[28] Stanely M, Prince P, Menon VP. Antioxidant action of Tinospora cordifolia root extract in alloxan diabetic rats. Phytother Res 2001;15:213-8.
[29] Prince PS, Menon VP. Antioxidant activity of Tinospora cordifolia roots in experimental diabetes. J Ethnopharmacol 1999;65:277-81.
[30] Mathew S, Kuttan G. Antioxidant activity of Tinospora cordifolia and its usefulness in the amelioration of cyclophosphamide-induced toxicity. J Exp Clin Cancer Res 1997;16:407-11.
[31] Gupta SS, Varma SCL, Garg VP, Rai M. Antidiabetic effect of Tinospora cordifolia. I. Effect on fasting blood sugar level, glucose tolerence and adrenaline induced hyperglycemia. Indian J Exp Biol 1967;55:733-45.
[32] Grover JK, Vats V, Rathi SS, Dawar R. Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. J Ethnopharmacol 2001;76:233-8.
[33] Thatte UM, Dahanukar SA. Immunotherapeutic modification of experimental infections by Indian medicinal plants. Phytother Res 1989;3:43-9.
[34] Thatte UM, Chhabria S, Karandikar SM, Dahanukar SA. Immunotherapeutic modification of E.coli induced abdominal sepsis and mortality in mice by Indian medicinal plants. Indian Drugs 1987;25:95-7. 90 TINOSPORA CORDIFOLIA: CHEMISTRY AND MEDICINAL PROPERTIES
[35] Rege NN, Nazareth HM, Bapat RD, Dahanukar SA. Modulation of immunosuppression in obstructive jaundice by Tinospora cordifolia. Indian J Med Res 1989;90:478-83.
[36] Manjrekar PN, Jolly CI, Narayanan S. Comparative studies of the immunomodulatory activity of Tinospora cordifolia and Tinospora sinensis. Fitoterapia 2000;71:254-7.
[37] Dikshit V, Damre AS, Kulkarni KR, Gokhale A, Saraf MN. Preliminary screening of imunocin for immunomodulatory activity. Indian J Pharm Sci 2000;62:257.
[38] Dahanukar SA, Thatte UM, Pai N, More PB, Karandikar SM, et al. Immunotherapeutic modification by Tinospora cordifolia of abdominal sepsis induced by caecal ligation in rats. Indian J Gastroenterol 1988;7:21-3.
[39]. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res 1999;13:275-91.
[40] Jana U, Chattopadhyay RN, Shw BP. Preliminary studies on anti-inflammaory activity of Zingiber officinale Rosc., Vitex negundo Linn. and Tinospora cordifolia (Willid) Miers in albino rats. Indian J Pharm 1999;31:232-233.
[41] Stanely M, Prince P, Menon VP, Gunasekaran G. Hypolipidaemic action of Tinospora cordifolia roots in alloxan diabetic rats. J Ethnopharmacol 1999;64:53-7.
[42] Gupta KC, Viswanathan R. Antituberculous substances from plants. Antibiot & Chemother 1956;6:194-5.
[43] Vedavathy S, Rao KN. Antipyretic activity of six indigenous medicinal plants of Tirumala Hills, Andhra Pradesh, India. J Ethnopharmacol 1991;33:193-6.
[44] Sudhakaran, D. S., Srirekha, P., Devasree, L. D., Premsingh, S., & Michael, R. D. Immunostimulatory effect of Tinospora cordifolia Miers leaf extract in Oreochromis mossambicus. Indian Journal of Experimental Biology Vol. 44, September 2006, pp 726-732.
[45] More, P., Pai, K. Immunomodulatory effects of Tinospora cordifolia (Guduchi) on macrophage activation. Biology and Medicine, 3 (2) Special Issue: 134-140, 2011.
[46] Upadhyay, A. K., Kumar, K., Kumar, A., and Mishra, H. S. Tinospora cordifolia (Willd.) Hook. f. and Thoms. (Guduchi) – validation of the Ayurvedic pharmacology through experimental and clinical studies.
[47] Castillo, A. L., Ramos, J. D. A., Francia, J. L. D., Quilala, P. F., Dujunco, M. U. Immunomodulatory Effects of Tinospora cordifolia Lotion on Interleukin-1, Interleukin-6 and Interleukin-8 Levels In Scabies-Infected Pediatric Patients: A Single Blind, Randomized Trial. International Journal of Pharmaceutical Sciences and Drug Research 2014; 6(3): 178-1.
[48] Subramanian, M., Chintalwar, G. J., Chattopadhyay, S. Antioxidant properties of a Tinospora cordifolia polysaccharide against iron-mediated lipid damage and Ɣ-ray induced protein damage. Redox Report, 7:3, 137-143, DOI:10.1179/135100002125000370.
[49] Stanely, P., Prince, M., Menon, V. P. Hypoglycaemic and other related actions of Tinospora cordifolia roots in alloxan-induced diabetic rats. Journal of Ethnopharmacology 70 (2000) 9–15.
[50] Stanely, P., Prince, M., Menon, V. P. Hypoglycaemic and Hypolipidaemic Action of Alcohol Extract of Tinospora cordifolia Roots in Chemical Induced Diabetes in Rats. Phytother. Res. 17, 410–413 (2003).
[51] Agarwal, A., Malini, S., Bairy, K. L., Rao, M. S. Effect of Tinospora Cordifolia on Learning and Memory in Normal and Memory Deficit Rats. Indian Journal of Pharmacology 2002; 34: 339-349.
[52] Nayampalli, S. S., Desai, N. K., And Ainapure S. S. Antiallergic properties of Tinospora Cordifolia in Animal Models. Indian J. Pharmac(1986) I8::250-252.
[53] Thatte, U. M., Kulkarni, M. R., Dahanukar, S. A. Immunotherapeutic modification of Escherichia coli peritonitis and bacteremia by Tinospora cordifolia. J Postgrad Med 1992;38:13-5.
[54] Panossian, A., and Wagner, H. 2011. Adaptogens, A Review of their History, Biological Activity, and Clinical Benefits. Eleuthero Eleutherococcus senticosus, Herbalgram 90.
[55] Panossian, A., and Wikman, G. Effect of adaptogens on the central nervous system. Arquivos Brasileiros de Fitomedicina Científica • Vol. 3 • número 1, April 2005.
[56] Parmar, B. J., and S.A. Kolhapure, S. A. Evaluation of efficacy and safety of Septilin Junior tablets in recurrent upper respiratory tract infections in children. The Antiseptic (2004): (101), 5, 191-197.
[57] Yusro, F., Mariani, Y., Diba, F., and Ohtani, K. Inventory of Medicinal Plants for Fever Used by Four Dayak Sub Ethnic in West Kalimantan, Indonesia. Kuroshio Science 8-1, 33-38, 2014.
[58] Raut, A. A., Joshi, A. D., Antarkar, D. S., Joshi, V. R., And Vaidya, A. B.. Anti-Rheumatic formulations from Ayurveda. Ancient Science of Life, Vol No. XI No.1 & 2, July & October 1991, Pages 66 - 69.
[59] Vikram, S. S., Singh, M., Singh, R., Rai, I. C., Kavitha, M., and Rohit. R. Clinical Study on Amavata with special reference to juvenile Rheumatoid Arthritis by Pippali Vardhamana Rasayana. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Volume 3, Issue 4, 1176-1188.
[60] Palep, H. S. Role of Herbal Immunomodulators and Antioxidants in Recurrent Pregnancy Loss. Bombay Hospital Journal, 28 July 2015.
[61]  Raj, G. R. A., Shailaja, U., Debnath, P., Banerjee, S., Rao, P. N. Exploratory studies on the therapeutic effects of Kumarabharana Rasa in the management of chronic tonsillitis among children at a tertiary care hospital of Karnataka. Journal of Traditional and Complementary Medicine Volume 6, Issue 1, January 2016, Pages 29-33.
[62] Debnath P, Banerjee S, Debnath PK. Ayurnutrigenomics: traditional knowledge inspired approach towards personalized nutrition. In: Ghosh D, Bagchi D, Konishi T, eds. Clinical Aspects of Functional Foods and Neutraceuticals. Florida: CRC Press; 2014:423-444.
[63] Uthayakumar et. al. Effect of Azadirachta indica Leaf Soluble Fraction on Immune Response and Disease Resistance in Channa striatus Against Tropical Freshwater Fungal Parasite Aphanomyces invadans (EUS). Global Veterinaria 13 (3): 355-364, 2014.
[64] Harikrishnan, R., C. Balasundaram and M.S. Heo, 2011. Impact of plant products on innate and adaptive immune system of cultured finfish and shellfish. Aquaculture, 317:1-15.
[65] Alexander, C.P., C.J.W Kirubakaran, R.D. Michael, 2010. Water soluble fraction of Tinospora cordifolia leaves enhanced the non-specific immune mechanisms and disease resistance in Oreochromis mossambicus. Fish and Shellfish Immunology, 29: 765-772.
[66] Arya, S., and Sharma, J. Tinospora Cordifolia (Miers) extract provides protection against Radiation induced alterations in intestinal Mucosa of swiss Albino Mouse. Pharmacologyonline 1: 293-313 (2010).
[67] Rajasekar, T., Usharani, J., Sakthivel, J., and Deivasigamani, B.,  Immunostimulatory effects of Cardiospermum halicacubum against Vibrio parahaemolyticus on tiger shrimp Penaeus monodon. J. Chem. Pharm. Res., 2011, 3(5):501-513.
[68] Magnadottir, B. Fish and Shellfish Immuno., 2006. 20, 137–151.
[69] Chi, S., She, G., Han, D., Wang, W., Liu, Z., and Liu. B. Genus Tinospora: Ethnopharmacology, Phytochemistry, and Pharmacology. Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 9232593, 32 pages.
[70] K. Ohtani, K. Okai, U. Yamashita, I. Yuasa, and A. Misaki, “Characterization of an acidic polysaccharide isolated from the leaves of Corchorus olitorius (Moroheiya),” Bioscience, Biotechnology, and Biochemistry, vol. 59, no. 3, pp. 378–381, 1995.
[71] Gacche, R. N., & Dhole, N. A. Antioxidant and Possible Anti-Inflammatory Potential of Selected Medicinal Plants Prescribed in the Indian Traditional System of Medicine. Pharmaceutical Biology, 44:5, 389-395.
[72] Bilfinger TV, George BS (2002): The role of protease inhibition with emphasis on the effects of inflammation and vascular immune phenomena. Curr Pharm Design 8: 125–133.
[73] Yuandani, Jantan, I., Ilangkovan, M., Husain, K., Chan, K. M. Inhibitory effects of compounds from Phyllanthus amarus on nitric oxide production, lymphocyte proliferation, and cytokine release from phagocytes. Drug Design, Development and Therapy 2016:10 1935–1945.
[74] Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–175.
[75] Kulkarni, A. P., Kellaway, L. A., and Kotwal, G. J. Herbal Complement Inhibitors in the Treatment of Neuroinflammation Future Strategy for Neuroprotection. Ann. N.Y. Acad. Sci. 1056: 413–429 (2005).
[76] Nair, P. K. R., Melnick, S. J., Ramachandran, R., Escalon, E., Ramachandran, C. Mechanism of macrophage activation by (1,4)-α-d-glucan isolated from Tinospora cordifolia.International Immunopharmacology, Volume 6, Issue 12, 5 December 2006, Pages 1815-1824.
[77] Mittal A., Singh R.P. (2009) Anticancer and Immunomodulatory Properties of Tinospora. In: Ramawat K. (eds) Herbal Drugs: Ethnomedicine to Modern Medicine. Springer, Berlin, Heidelberg.
[78] Gupta, A. K., Sannat, C., Agrawal, R., Hirpurkar, S. D. Effect of feeding of 'Tinospora cordifolia' on immune response in cattle. Journal of Animal Research, Vol. 6, No. 4, Aug 2016: 579-584.
[79] Raghua, R., Sharma, D., Ramakrishnan, R., Khanam, S., Chintalwar, G. J., Sainis, K. B. Molecular events in the activation of B cells and macrophages by a non-microbial TLR4 agonist, G1-4A from Tinospora cordifolia. Immunology Letters Volume 123, Issue 1, 24 March 2009, Pages 60-71.
[80] Singh, N., Singh, S. M., & Shrivastava (2008). P. Effect of Tinospora Cordifolia on the Antitumor Activity of Tumor-Associated Macrophages–Derived Dendritic Cells. Immunopharmacology and Immunotoxicology, 27:1, 1-14, DOI: 10.1081/IPH-51287.
[81] Bertsias, G., Cervera, R., Boumpas, D. T. EULAR Textbook on Rheumatic Diseases. (Ch-22 - Systemic Lupus Erythematosus: Pathogenesis 20 and Clinical Features).
[82] Mosca, M., Irastorza, G. R., Khamashta, M. A., Hughes, G. R. V. Treatment of systemic lupus erythematosus. International Immunopharmacology 1 (2001) 1065-1075.
[83] Vitali C, Doria A, Tincani A, Fabbri P, Balestrieri G, Galeazzi M, et al. International survey on the management of patients with SLE: I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol 1996;14 (Suppl. 16) :17–22.
[84] Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243–63.
[85] Tam LS, Gladman DD, Urowitz MB, Rahman P, Hallett D. Effect of antimalarial on the fasting lipid profile in systemic lupus erythematosus abstract . Arthritis Rheum 1999;42: S149.
[86] Vera O, Ariza R, Barile L. Controlled clinical trial of chloroquine in the serum levels of cholesterol, triglicerides, very low density lipoproteins, high density lipoproteins and low density lipoproteins in SLE patients abstract . Arthritis Rheum 1999;42:S148.
[87] Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 1999;26:808–15.
[88] Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tseng S, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999;7: 545–51.
[89] D’Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997;15:275–82.
[90] Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71:321–7.
[91] de Glas-Vos JW, Krediet RT, Weening JJ, Arisz L. Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine. Neth J Med 1995;46:4–14.
[92] Nossent HC, Koldingsbes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000;39:969–74.
[93] Bansal VK, Beto JA. Treatment of lupus nephritis: a metaanalysis of clinical trials. Am J Kidney Dis 1997;29:193–9.
[94] Austin III HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614–9.
[95] Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945–50.
[96] Boumpas DT, Austin III HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741–5.
[97] Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549–57.
[98] Donadio JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151–5.
[99] Balow JE, Austin HA, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311:491–5.
[100] Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996;35:669–75.
[101] Schiel R, Bambauer R. Therapeutic plasma exchange and cyclosporine in the treatment of systemic lupus erythematosus. Ther Apheresis 1999;3:234–9.
[102] Sherer Y, Langevitz P, Levy Y, Fabrizzi F, Shoenfeld Y. Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Lupus 1999;8: 324–7.
[103] Sugiyama M, Ogasawara H, Kaneko H, Hishikawa T, Sekigawa I, Iida N, et al. Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus. Lupus 1998;7:53–6.
[104] Tokuda M, Kurata N, Mizoguchi A, Inoh M, Set K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994;37: 551–8.
[105] Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40:27–35.
[106] Dostal C, Tesar V, Rychlik I, Zabka J, Vencovsky J, Bartunkova J, et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998;7:29–36.
[107] Radhakrishnan J, Kunis A, D’Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147–54.
[108] Tam LS, Li EK, Leung CB, Wong KC, Lai FMM, Wang A, et al. Long-term treatment of lupus nephritis with cyclosporin A. Q J Med 1998;91:573–80.
[109] Carneiro JR, Sato EI. Double-blind, randomized, placebo controlled clinical trial of methotrexate in in systemic lupus erythematosus. J Rheumatol 1999;26:1275–9.
[110] McMurray RW, Elbourne KB, Lagoo A, Lal S. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB✕NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 1998;25:2364–70.
[111] Glickich D, Acharya A. Mycophenolate mofetil for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32:318–22.
[112] Briggs WA, Choi MJ, Scheel PJ. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31:213–7.
[113] Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731–6.
[114] Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10: 833–9.
[115] Petri M. Mycophenolate mofetil treatment of systemic lupus erythematosus abstract . Arthritis Rheum 1999;42:S303.
[116] Burt RB, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune diseases by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505–14.
[117] Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R, et al. Autologous peripheral blood stem and progenitor CD34 Ž . q cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus 1998;7:492–4.
[118] Traynor A, Burt RK. Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology 1999;38:767–72.
[119] Marmont AM. Intense immunosuppression and stem cell transplantation or rescue for severe systemic lupus erythematosus. Lupus 1999;8:256–7.
[120] Fouillard L, Gorin NC, Laporte JPH, Leon A, Brantus JF, Miossec P. Control of severe systemic lupus erythematosus after high-dose immunosuppressive therapy and transplantation of CD34q purified and autologous stem cells from peripheral blood. Lupus 1999;8:320–3.
[121] Trysberg E, Lindgren I, Tarkowski A. Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus. Ann Rheum Dis 2000;59:236–8.
[122] Hiepe F, Rosen O, Thiel A, Massenkeil G, Radtke H, Haupl T, et al. Successful treatment of refractory systemic lupus erythematosus SLE by autologous stem cell transplantation ASCT with in vivo immunoablation and ex vivo depletion of mononuclear cells abstract . Arthritis Rheum 1999;42: S170.
[123] Fenton DA, Black MM. Low dose dapsone in hte treatment of subacute cutaneous lupus erythematosus. Clin Exp Rheumatol 1986;11:102–3.
[124] Lindskov R, Reymann F. Dapsone in the treatment of discoid lupus erythematosus. Dermatologica 1986;172:214–7.
[125] Nishina M, Saito E, Kinoshita M. Correction of severe leukocytopenia and thrombocytopenia in systemic lupus erythematosus by treatment with Dapsone. J Rheumatol 1997; 24:811–2.
[126] Callen JP. Management of antimalarial refractory cutaneous lupus erythematosus. Lupus 1997;6:203–8.
[127] Naafs B, Bakkers EJ, Flinterman J, Faber WR. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982;107:83–6.
[128] Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108:461–6.
[129] Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826–31.
[130] Van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998;25:285–9.
[131] Davis JC, Austin H, Boumpas D, Fleisher TA, Yarboro C, Larson A, et al. A pilot study of 2-chloro-2X-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998;41:335–43.
[132] Houssiau FA, Delannoy A, Devogelaer JP. Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al. Arthritis Rheum 1998;41:1704–5.
[133] Kontogiannis V, Lanyon PC, Powell RJ. Cladribine in the treatment of systemic lupus erythematosus nephritis. Ann Rheum Dis 1999;58:653.
[134] Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol 1999;52:67–75.
[135] Viallard JF, Mercie P, Faure I, Pellegrin JL, Leng B. Successful treatment of lupus with fludarabine. Lupus 1999;8: 767–9.
[136] Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997;56:690–2.
[137] Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black✕New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159–64.
[138] Weisman MH, Bluestein HG, Berner CM, De Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314–8.
[139] Guglielmotti A, Aquilini L, D’Onofrio E, Rosignoli MT, Milanese C, Pinza M. Bindarit prolongs survival and reduce renal damage in NZB/W lupus mice. Clin Exp Rheumatol 1998;16:149–54.
[140] Boumpas DT, Austin III HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366–9.
[141] Ochonisky S, Veeroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994;130: 66–9.
[142] Davis JC, Ttoritis MC, Skenar TA, Wofsy D. Results of a phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody IDEC-131 in patients with systemic lupus erythematosus SLE abstract . Arthritis Rheum 1999;42:S281.
[143] Sherer Y, Shoenfeld Y. Stem cells transplantation—a cure for autoimmune disease. Lupus 1998;7:137–40.
[144] Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008:58:2453–2459.
[145] Bertsias et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195–205.
[146] Pathak and Mohan Arthritis Research & Therapy 2011, 13:241.
[147] Ramanujam, M. and Davidson, A. Targeting of the immune system in systemic lupus erythematosus. Expert reviews in Molecular Medicine Vol. 10; e2; January 2008.
[148] Neto, N. S. R., Bonfiglioli, K. R., Milanez, F. M., Macêdo, P. A., Levy-Neto, M. Lymphadenopathy and systemic lupus erythematosus. Bras J Rheumatol 2010;50(1):96-101.
[149] Daruwala, C., Mercogliano, G., and Harder, T. P. Gastrointestinal Manifestations of Systemic Lupus Erythematosus and Scleroderma.
[150] Hamel-Roy J, Devroede G, Arhan P, et al. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology. 1985;88:1–7.
[151] Cuchacovich, R., Gedalia, A. Pathophysiology and Clinical Spectrum of Infections in Systemic Lupus Erythematosus. Rheum Dis Clin N Am 35 (2009) 75–93.
[152] Ponticelli, C., and Moroni, G. Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). Pharmaceuticals 2010, 3, 300-322.
